# Preoperative Stereotactic Ablative Body Radiotherapy (SABR) for Early-Stage Breast Cancer

> **NCT03137693** · NA · TERMINATED · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 20 (actual)

## Conditions studied

- Breast Cancer
- Breast Cancer Female
- Breast Adenocarcinoma

## Interventions

- **OTHER:** Standard of Care Schedule Variation: SABR
- **PROCEDURE:** Breast-conserving Surgery

## Key facts

- **NCT ID:** NCT03137693
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-11-29
- **Primary completion:** 2019-11-01
- **Final completion:** 2020-01-27
- **Target enrollment:** 20 (ACTUAL)
- **Why stopped:** no responders/lack of efficacy
- **Last updated:** 2023-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03137693

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03137693, "Preoperative Stereotactic Ablative Body Radiotherapy (SABR) for Early-Stage Breast Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03137693. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*